Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Allopurinol

FDA-approved product (tablet, oral), marketed as Allopurinol, Lopurin, Zyloprim and 2 more.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Allopurinol
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Gout
  • Leukemia
  • Lymphoma
  • Response Evaluation Criteria in Solid Tumors

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Preparations inhibiting uric acid production
FDA pharmacologic class
Xanthine Oxidase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Allopurinol, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA19.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli24.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis2.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 0 of 1 lab record
Open Allopurinol in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Allopurinol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Allopurinol and Endothelial Function in Diabetic CAD Patients

    NCT03385135 · start 2017-12

    Registered record
    Registry ID
    NCT03385135
    Conditions
    Diabetes Mellitus; Coronary Artery Disease
    Interventions
    Allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-12
    Completion
    2018-06
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus; Coronary Artery Disease
    InterventionAllopurinol
    PhaseNot applicable
    Registry statusUnknown

  • Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.

    NCT03272425 · start 2017-08-14

    Registered record
    Registry ID
    NCT03272425
    Conditions
    Gout
    Interventions
    lesinurad/allopurinol 200/300 FDC tablets; lesinurad 200 mg; allopurinol 300 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-08-14
    Completion
    2017-10-04
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout
    Interventionlesinurad/allopurinol 200/300 FDC tablets; lesinurad 200 mg; allopurinol 300 mg
    PhasePhase 1
    Registry statusCompleted

  • A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

    NCT03226899 · start 2017-07-19

    Registered record
    Registry ID
    NCT03226899
    Conditions
    Gout; Chronic Kidney Disease (CKD)
    Interventions
    Lesinurad; XOI; Placebo; colchicine; corticosteroids
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-07-19
    Completion
    2019-02-25
    Enrolment
    242

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout; Chronic Kidney Disease (CKD)
    InterventionLesinurad; XOI; Placebo; colchicine +1 more
    PhasePhase 4
    Registry statusTerminated

  • HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction

    NCT03046914 · start 2016-02-24

    Registered record
    Registry ID
    NCT03046914
    Conditions
    Stevens-Johnson Syndrome; Kidney Failure, Chronic
    Interventions
    HLA-B*5801 test
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2016-02-24
    Completion
    2017-11-30
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStevens-Johnson Syndrome; Kidney Failure, Chronic
    InterventionHLA-B*5801 test
    PhaseNot applicable
    Registry statusUnknown

  • Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Pyrazinamide Plus Allopurinol in Healthy Volunteers

    NCT02700347 · start 2016-02

    Registered record
    Registry ID
    NCT02700347
    Conditions
    Tuberculosis
    Interventions
    Pyrazinamide; Allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-02
    Completion
    2016-04
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionPyrazinamide; Allopurinol
    PhasePhase 1
    Registry statusCompleted

  • Allopurinol in Functional Impairment (ALFIE) Trial: 'Improving Muscle Strength'

    NCT01550107 · start 2015-02-01

    Registered record
    Registry ID
    NCT01550107
    Conditions
    Sarcopenia
    Interventions
    Allopurinol; Lactose tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-02-01
    Completion
    2017-09-20
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcopenia
    InterventionAllopurinol; Lactose tablets
    PhasePhase 4
    Registry statusCompleted

  • Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines

    NCT02797028 · start 2015-01

    Registered record
    Registry ID
    NCT02797028
    Conditions
    Cardiovascular Disease
    Interventions
    Anthocyanidins capsule; Placebo capsule; Allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-01
    Completion
    2017-12
    Enrolment
    320

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Disease
    InterventionAnthocyanidins capsule; Placebo capsule; Allopurinol
    PhasePhase 4
    Registry statusUnknown

  • Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML

    NCT02214407 · start 2014-10-14

    Registered record
    Registry ID
    NCT02214407
    Conditions
    MDS
    Interventions
    Decitabine; HYDROXYUREA
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-10-14
    Completion
    2021-08-16
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMDS
    InterventionDecitabine; HYDROXYUREA
    PhasePhase 3
    Registry statusCompleted

  • Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients

    NCT02063997 · start 2014-03

    Registered record
    Registry ID
    NCT02063997
    Conditions
    Gout
    Interventions
    Arhalofenate 600 mg; Allopurinol 300 mg; Colchicine 0.6 mg; Placebo; Arhalofenate 800 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-03
    Completion
    2015-01
    Enrolment
    248

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout
    InterventionArhalofenate 600 mg; Allopurinol 300 mg; Colchicine 0.6 mg; Placebo +1 more
    PhasePhase 2
    Registry statusCompleted

  • A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes

    NCT02017171 · start 2014-02

    Registered record
    Registry ID
    NCT02017171
    Conditions
    Diabetic Nephropathies; Coronary Artery Disease
    Interventions
    Allopurinol; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-02
    Completion
    2019-08-31
    Enrolment
    530

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Nephropathies; Coronary Artery Disease
    InterventionAllopurinol; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Allopurinol in Acute Coronary Syndrome

    NCT01457820 · start 2012-04

    Registered record
    Registry ID
    NCT01457820
    Conditions
    Chronic Stable Angina
    Interventions
    Allopurinol; Allopurinol; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2012-04
    Completion
    2015-03
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Stable Angina
    InterventionAllopurinol; Allopurinol; Placebo
    PhasePhase 4
    Registry statusTerminated

  • Effect of Allopurinol Administration on the Prevention of Muscle Mass Loss in Subject Immobilized.

    NCT01987570 · start 2012-04

    Registered record
    Registry ID
    NCT01987570
    Conditions
    Patients With Grade II Ankle Sprain
    Interventions
    Allopurinol; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-04
    Completion
    2016-07
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients With Grade II Ankle Sprain
    InterventionAllopurinol; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Combining Lesinurad With Allopurinol in Inadequate Responders

    NCT01493531 · start 2011-12

    Registered record
    Registry ID
    NCT01493531
    Conditions
    Gout
    Interventions
    Lesinurad; Lesinurad; Placebo; Allopurinol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-12
    Completion
    2014-07
    Enrolment
    610

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout
    InterventionLesinurad; Lesinurad; Placebo; Allopurinol
    PhasePhase 3
    Registry statusCompleted

  • Role of Allopurinol on Oxidative Stress and Mitochondrial Alterations in Skeletal Muscle of Diabetic Patients

    NCT02533648 · start 2011-09-16

    Registered record
    Registry ID
    NCT02533648
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    2 capsules of allopurinol 150 mg daily for 3 month; 2 capsules of lactose daily for 3 month
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-09-16
    Completion
    2016-02-18
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    Intervention2 capsules of allopurinol 150 mg daily for 3 month; 2 capsules of lactose daily for 3 month
    PhasePhase 3
    Registry statusCompleted

  • Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function

    NCT01320722 · start 2011-03

    Registered record
    Registry ID
    NCT01320722
    Conditions
    Renal Function; Endothelial Function; Blood Pressure; Overweight; Obesity
    Interventions
    Vitamin D ergocalciferol; Probenecid; Allopurinol; Placebo; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-03
    Completion
    2015-06
    Enrolment
    242

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Function; Endothelial Function; Blood Pressure; Overweight +1 more
    InterventionVitamin D ergocalciferol; Probenecid; Allopurinol; Placebo +1 more
    PhasePhase 3
    Registry statusCompleted